Lilly plans to build four new pharmaceutical plants in the US, creating 13,000 jobs and bringing its recent domestic ...
Investor's Business Daily on MSN2h
Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats UpHims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a ...
Supplies of high-demand obesity treatments are improving, but that doesn’t mean it’s easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key ...
Eli Lilly and Company, Hims & Hers Health, UnitedHealth Group, Walmart, Tempus AI, Johnson & Johnson, and Merck & Co., Inc. are the seven Medical stocks to watch today, according to MarketBeat’s stock ...
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Eli Lilly ...
People taking Zepbound, or interested in starting, will now have several vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 ...
Simlandi and adalimumab-adaz have been with on formulary, along with Humira, beginning Jan. 1, 2025, Arpit Patel, Pharm.D., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback